Latest news from Sangart on Newswise en-us Copyright 2024 Newswise 115 31 / /images/newswise-logo-rss.gif /articles/sangart-reports-positive-phase-iia-data-for-novel-oxygen-therapeutic-agent-mp4ox-in-severe-trauma-patients/?sc=rsin /articles/sangart-reports-positive-phase-iia-data-for-novel-oxygen-therapeutic-agent-mp4ox-in-severe-trauma-patients/?sc=rsin Tue, 31 Aug 2010 09:00:00 EST Sangart, Inc., today announced positive results from its Phase IIa proof-of-concept study of MP4OX (oxygenated pegylated hemoglobin) in severely injured trauma patients with hemorrhagic shock causing lactic acidosis. Sangart